GSK bets on activin signalling with $950m 35Pharma acquisition

GlaxoSmithKline plc (GSK) has agreed to acquire privately held 35Pharma Inc. for $950 million in cash, securing HS235, a late preclinical to early clinical activin signalling inhibitor positioned for pulmonary hypertension indications. The transaction expands GlaxoSmithKline plc’s Respiratory, Immunology and Inflammation pipeline at a time when pulmonary hypertension drug development is shifting from vasodilation toward disease-modifying biology and metabolic comorbidity management.

Why is GlaxoSmithKline plc paying nearly $1 billion for a Phase I–stage pulmonary hypertension asset now?

At first glance, the valuation attached to 35Pharma Inc. appears aggressive given HS235 has only completed Phase I studies in healthy volunteers. The strategic rationale becomes clearer when viewed against the evolving pulmonary hypertension market, where biologics targeting the activin signalling pathway are emerging as the next competitive battleground.

Pulmonary hypertension remains a progressive, life-shortening condition with limited therapeutic innovation over the past decade. Existing therapies primarily manage symptoms by targeting vasodilation pathways, leaving substantial unmet need for agents that address vascular remodelling, inflammation, and right-heart dysfunction. Activin signalling inhibitors represent one of the few mechanisms with human validation that suggests disease-modifying potential rather than incremental symptom control.

By acquiring HS235 outright rather than licensing it, GSK is effectively securing long-term optionality over a mechanism that could define the next decade of pulmonary hypertension care. The $950 million cash price reflects not current clinical maturity, but the scarcity value of differentiated activin pathway assets and the projected $18 billion pulmonary hypertension market expected by 2032, with activin inhibitors potentially accounting for half of that value.

How does HS235 differ from existing activin signalling inhibitors used in pulmonary hypertension?

HS235 is designed to selectively inhibit activin receptor signalling while reducing binding to BMP9 and BMP10, ligands associated with bleeding and vascular adverse events seen with earlier generation agents. This selectivity is not a minor medicinal chemistry detail but a critical differentiator in a patient population where anticoagulant and antiplatelet therapy is common.

Bleeding risk has emerged as a practical ceiling for broader use of some activin pathway therapies, particularly in older pulmonary hypertension populations and those with comorbid cardiovascular disease. By engineering HS235 to reduce interaction with pathways implicated in telangiectasia and hemorrhagic complications, 35Pharma Inc. has attempted to widen the therapeutic window of the class.

If this selectivity translates clinically, GSK could position HS235 not merely as another pulmonary arterial hypertension drug, but as a platform asset suitable for combination regimens and earlier lines of therapy, where safety constraints are often more restrictive.

Why are the metabolic effects of HS235 strategically important for GSK’s pipeline?

One of the more underappreciated aspects of the acquisition is HS235’s reported metabolic profile. Early clinical observations suggest potential fat-selective weight loss, preservation of lean mass, and improved insulin sensitivity, supported by favourable changes in adipokines and inflammatory markers.

Pulmonary hypertension patients increasingly present with obesity, insulin resistance, and cardiometabolic dysfunction, particularly in pulmonary hypertension associated with heart failure with preserved ejection fraction. Traditional pulmonary vasodilators do little to address these systemic drivers of disease progression.

For GSK, the metabolic signal around HS235 opens strategic doors beyond pulmonary hypertension. It aligns with a broader Respiratory, Immunology and Inflammation portfolio ambition to address chronic diseases where vascular, metabolic, inflammatory, and fibrotic pathways intersect. This could enable lifecycle expansion into adjacent cardiopulmonary or metabolic-inflammatory indications if clinical data supports it.

What does this deal signal about GSK’s capital allocation strategy in Respiratory, Immunology and Inflammation?

The acquisition reinforces a noticeable shift in GSK’s dealmaking posture toward targeted, biology-driven assets with platform potential rather than late-stage commercial bolt-ons. Following the separation of its consumer healthcare business, the company has shown greater willingness to deploy capital into differentiated science with long development runways.

At $950 million in cash, the transaction is material but not balance-sheet stretching for GSK. It reflects confidence in internal development capabilities and a preference for full ownership of assets where integration, prioritisation, and indication sequencing can be tightly controlled.

Importantly, the deal also signals a willingness to compete directly in biologics-heavy cardiopulmonary spaces where execution risk is high but upside is asymmetric. This contrasts with a more conservative licensing approach that might limit long-term value capture.

How competitive is the pulmonary hypertension pipeline landscape GSK is entering?

Pulmonary hypertension drug development is entering a crowded but still immature phase. Multiple companies are pursuing activin pathway modulation, while others are exploring novel antifibrotic, anti-inflammatory, and right-ventricular support mechanisms.

Competition will likely intensify around differentiation on safety, durability of response, and ability to address comorbid metabolic disease. HS235’s selectivity claims position it well on paper, but head-to-head differentiation will ultimately depend on clinical outcomes in real-world pulmonary hypertension populations.

GSK’s advantage lies in its global respiratory franchise, relationships with specialist centres, and ability to run large, complex cardiopulmonary trials. These capabilities could allow HS235 to move efficiently through development if early signals hold.

What are the key clinical and regulatory risks that could still derail HS235’s development?

Despite the strategic logic, execution risk remains substantial. HS235 has yet to generate efficacy data in pulmonary arterial hypertension or pulmonary hypertension due to heart failure with preserved ejection fraction. Phase I safety and biomarker signals, while encouraging, do not guarantee clinical benefit in heterogeneous patient populations.

Regulatory expectations in pulmonary hypertension are evolving, with increasing scrutiny on meaningful functional endpoints, long-term safety, and real-world applicability. Demonstrating reduced bleeding risk compared to existing therapies will require carefully designed trials and sufficient patient exposure.

There is also the risk that metabolic benefits observed early may not translate into durable clinical advantages or may complicate regulatory positioning if weight or metabolic changes become confounding variables in efficacy assessments.

How are investors likely to interpret this acquisition in the near and medium term?

From an investor perspective, the acquisition is unlikely to materially move GSK’s share price in the short term. The asset is early, revenue contribution is distant, and the market typically discounts Phase I biology until proof-of-concept data emerges.

However, institutional investors focused on pipeline quality may view the deal positively as evidence that GSK is replenishing its Respiratory, Immunology and Inflammation portfolio with assets that reflect where science is moving rather than where it has been.

Over the medium term, sentiment will hinge on early Phase II readouts, safety differentiation versus competing activin inhibitors, and clarity on whether HS235 can realistically support multiple indications. Success would validate GSK’s post-consumer-healthcare R&D strategy. Failure would reinforce concerns about high-priced early-stage acquisitions in biologics-heavy indications.

What does this transaction suggest about the future direction of pulmonary hypertension drug development?

The deal underscores a broader industry pivot away from purely haemodynamic management toward integrated approaches that address vascular remodelling, inflammation, and systemic metabolic dysfunction. Pulmonary hypertension is increasingly viewed not as a standalone pulmonary disease but as a multisystem disorder.

If HS235 delivers on its promise, it could accelerate this shift and force competitors to rethink pipeline strategies that focus narrowly on pulmonary vasodilation. Even if HS235 itself falls short, GSK’s move signals that large pharmaceutical companies are willing to pay for early access to biology that reframes how pulmonary hypertension is treated.

Key takeaways: What GSK’s acquisition of 35Pharma Inc. means for investors and the pulmonary hypertension market

• GSK is making a deliberate $950 million bet on activin signalling inhibition as a next-generation pulmonary hypertension strategy

• HS235’s value lies less in current clinical stage and more in its potential safety differentiation and metabolic profile

• Reduced bleeding risk could materially expand the addressable pulmonary hypertension population if validated clinically

• Metabolic effects position HS235 as a possible platform asset beyond pulmonary hypertension alone

• The deal reflects GSK’s post-consumer-healthcare shift toward high-conviction, biology-driven acquisitions

• Clinical execution risk remains high given limited efficacy data in target patient populations

• Investor reaction is likely to be neutral short term but sensitive to early Phase II outcomes

• The transaction reinforces a broader industry pivot toward disease-modifying pulmonary hypertension therapies